Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The latest announcement is out from Akebia Therapeutics ( (AKBA) ).
Akebia Therapeutics has entered a multi-year commercial supply agreement with a leading dialysis organization to provide access to its drug Vafseo® (vadadustat) for dialysis patients. This strategic move could enhance Akebia’s market presence in the dialysis segment, offering potential growth opportunities.
Learn more about AKBA stock on TipRanks’ Stock Analysis page.
